


**Product Name** : Palazestrant  
**Cat. No.** : PC-20547  
**CAS No.** : 2092925-89-6  
**Molecular Formula** : C<sub>28</sub>H<sub>36</sub>FN<sub>3</sub>O  
**Molecular Weight** : 449.6  
**Target** : Estrogen Receptor/ERR  
**Solubility** : 10 mM in DMSO



CAS: 2092925-89-6

1. Parisian AD, et al. *Mol Cancer Ther.* 2023 Dec

### Biological Activity

Palazestrant (OP-1250) is a potent, orally bioavailable complete **estrogen receptor (ER)** antagonist (IC<sub>50</sub>=6.4 nM) and selective ER degrader, blocks activity of both AF1 and AF2.

OP-1250 demonstrates no agonist-like cross-reactivity on glucocorticoid, progesterone, or androgen receptors.

OP-1250 blocks estrogen-induced transcriptional activity and lacks agonist activity on estrogen-induced genes.

OP-1250 displays in vitro and in vivo efficacy and degrades the ER in breast cancer models.

OP-1250 degrades ERα with comparable potency to fulvestrant (DC<sub>50</sub> 0.52 nM and 0.56 nM, respectively, in MCF7 cell line).

### References

16. doi: 10.1158/1535-7163.MCT-23-0351.

